{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:07:09Z","timestamp":1792858029430,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21904021"],"award-info":[{"award-number":["21904021"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62175031"],"award-info":[{"award-number":["62175031"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018534","name":"Medical Innovation Project of Fujian Province","doi-asserted-by":"publisher","award":["2021CXA043"],"award-info":[{"award-number":["2021CXA043"]}],"id":[{"id":"10.13039\/501100018534","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018534","name":"Medical Innovation Project of Fujian Province","doi-asserted-by":"publisher","award":["20220203"],"award-info":[{"award-number":["20220203"]}],"id":[{"id":"10.13039\/501100018534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ymthe.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T19:27:43Z","timestamp":1682278063000},"page":"2489-2506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Genetically engineered nanovesicles mobilize synergistic antitumor immunity by ADAR1 silence and PDL1 blockade"],"prefix":"10.1016","volume":"31","author":[{"given":"Lei","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4981","authenticated-orcid":false,"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.04.011_bib1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.04.011_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2023.04.011_bib3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2023.04.011_bib4","first-page":"1","article-title":"Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance","volume":"50","author":"Park","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymthe.2023.04.011_bib5","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41467-021-21921-x","article-title":"ADAR1 RNA editing enzyme regulates R-loop formation and genome stability at telomeres in cancer cells","volume":"12","author":"Shiromoto","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.04.011_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccell.2015.08.013","article-title":"The genomic landscape and clinical relevance of A-to-I RNA editing in human cancers","volume":"28","author":"Han","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2023.04.011_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.celrep.2015.08.080","article-title":"Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors","volume":"13","author":"Paz-Yaacov","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2023.04.011_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/genes10010012","article-title":"ADAR1 editing and its role in cancer","volume":"10","author":"Xu","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2023.04.011_bib9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","article-title":"Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade","volume":"565","author":"Ishizuka","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.04.011_bib10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.04.011_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.gene.2013.12.019","article-title":"Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies","volume":"538","author":"Deng","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2023.04.011_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.04.011_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine."},{"key":"10.1016\/j.ymthe.2023.04.011_bib14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154\u2013155","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2023.04.011_bib15","doi-asserted-by":"crossref","first-page":"1900795","DOI":"10.1002\/adma.201900795","article-title":"Engineering biomimetic platesomes for pH-responsive drug delivery and enhanced antitumor activity","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2023.04.011_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature15373","article-title":"Nanoparticle biointerfacing by platelet membrane cloaking","volume":"526","author":"Hu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.04.011_bib17","doi-asserted-by":"crossref","first-page":"101341","DOI":"10.1016\/j.isci.2020.101341","article-title":"Converting immune cold into hot by biosynthetic functional vesicles to boost systematic antitumor immunity","volume":"23","author":"Wu","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2023.04.011_bib18","doi-asserted-by":"crossref","first-page":"100324","DOI":"10.1016\/j.xpro.2021.100324","article-title":"Protocol to prepare functional cellular nanovesicles with PD1 and TRAIL to boost antitumor response","volume":"2","author":"Yu","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.ymthe.2023.04.011_bib19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41565-021-00972-7","article-title":"T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy","volume":"16","author":"Zhai","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2023.04.011_bib20","doi-asserted-by":"crossref","first-page":"e1707112","DOI":"10.1002\/adma.201707112","article-title":"PD-1 blockade cellular vesicles for cancer immunotherapy","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2023.04.011_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/138920110791111960","article-title":"Cell engineering and cultivation of Chinese hamster ovary (CHO) Cells","volume":"11","author":"Omasa","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymthe.2023.04.011_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T\u00a0cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2023.04.011_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2023.04.011_bib24","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.4049\/jimmunol.169.12.6842","article-title":"The roles of IL-12 in providing a third signal for clonal expansion of naive CD8\u00a0T Cells","volume":"169","author":"Valenzuela","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.04.011_bib25","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17425247.2019.1669558","article-title":"Lipid-based nanoparticle formulations for small molecules and RNA drugs","volume":"16","author":"Ickenstein","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2023.04.011_bib26","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1021\/jp303267y","article-title":"Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core","volume":"116","author":"Leung","year":"2012","journal-title":"J.\u00a0Phys. Chem. C"},{"key":"10.1016\/j.ymthe.2023.04.011_bib27","doi-asserted-by":"crossref","first-page":"36906","DOI":"10.1021\/acsami.0c09657","article-title":"Cancer cell-targeted photosensitizer and therapeutic protein co-delivery nanoplatform based on a metal-organic framework for enhanced synergistic photodynamic and protein therapy","volume":"12","author":"Ding","year":"2020","journal-title":"ACS Appl. Mater. Inter."},{"key":"10.1016\/j.ymthe.2023.04.011_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2023.04.011_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nnano.2010.277","article-title":"Statistical analysis of nanoparticle dosing in a dynamic cellular system","volume":"6","author":"Summers","year":"2011","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2023.04.011_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","article-title":"Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.04.011_bib31","doi-asserted-by":"crossref","first-page":"9763284","DOI":"10.34133\/2022\/9763284","article-title":"Breast cancer induced bone osteolysis prediction using temporal variational autoencoders","volume":"2022","author":"Xiong","year":"2022","journal-title":"BME Front."},{"key":"10.1016\/j.ymthe.2023.04.011_bib32","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ymthe.2023.04.011_bib33","doi-asserted-by":"crossref","first-page":"e1808200","DOI":"10.1002\/adma.201808200","article-title":"Biomimetic metal\u2013organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy","volume":"31","author":"Min","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2023.04.011_bib34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/mthe.2002.0568","article-title":"Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation","volume":"5","author":"Oupicky","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.04.011_bib35","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1002\/anie.200907210","article-title":"A tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery","volume":"49","author":"Du","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2023.04.011_bib36","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T\u00a0cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.04.011_bib37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-022-04753-7","article-title":"ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis","volume":"606","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.04.011_bib38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2023.04.011_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.04.011_bib40","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1021\/acs.nanolett.8b02321","article-title":"Engineering PD-1-presenting platelets for cancer immunotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett."},{"key":"10.1016\/j.ymthe.2023.04.011_bib41","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.04.011_bib42","doi-asserted-by":"crossref","first-page":"112176","DOI":"10.1016\/j.msec.2021.112176","article-title":"Engineering 2D approaches fibrous platform incorporating turmeric and polyaniline nanoparticles to predict the expression of \u03b2III-Tubulin and TREK-1 through qRT-PCR to detect neuronal differentiation of PC12 cells","volume":"127","author":"Shrestha","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ymthe.2023.04.011_bib43","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1039\/D0BM01034K","article-title":"Para-substituted sulfonic acid-doped protonated emeraldine salt nanobuds: a potent neural interface targeting PC12 cell interactions and promotes neuronal cell differentiation","volume":"9","author":"Shrestha","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ymthe.2023.04.011_bib44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623002095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623002095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:07:40Z","timestamp":1761502060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623002095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1525001623002095"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.04.011","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically engineered nanovesicles mobilize synergistic antitumor immunity by ADAR1 silence and PDL1 blockade","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}